FDA Approves Letermovir
FDA Approves Letermovir For Prophylaxis Of Cytomegalovirus Infection And Disease In Allogeneic Stem Cell Transplant Patients
- +91-8750295029
- [email protected]
- Delhi NCR
FDA Approves Letermovir For Prophylaxis Of Cytomegalovirus Infection And Disease In Allogeneic Stem Cell Transplant Patients
FDA approves treatment for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation
Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021
5th Global Summit on
Cancer and Oncology Research
October 21-22, 2021 Vienna, Austria
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.
777, Sector No. 37, Faridabad,
Haryana: 121003. India.
© 2024 All Rights Reserved.